Skip to main content
Premium Trial:

Request an Annual Quote

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group, a maker of lateral flow tests, says, according to the Financial Times.

It adds that while employer access to free tests has wound down in England, free lateral flow kits have still been publicly available at pharmacies or from a government website. Innova has in particular supplied the UK with more than 1.5 billion lateral flow devices under contracts worth more than £4 billion, FT says.

But Dan Elliott, Innova's chief executive, tells it that he would be "surprised" if free testing past the spring and that he was preparing for a shift to a retail environment. He notes, though, that the end date of the program would likely depend on SARS-CoV-2 infection rates.

As FT adds, there have been questions about the accuracy of lateral flow tests. In June, the US Food and Drug Administration warned against using the Innova test, saying that its performance has not been adequately established, as 360Dx reported then.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.